- All
- #InspiredByLife
- Bioeconomy
- Biosimilars
- BREXIT
- Cell & Gene Therapies
- Circular Economy
- Climate Change
- COVID-19
- Factsheet
- Genome editing
- HEALTHCARE BIOTECH
- INDUSTRIAL BIOTECH
- Innovation
- Intellectual Property
- Interview
- Jobs & Growth
- NATIONAL ASSOCIATIONS
- News
- Other
- Patient Bio-Forum
- Position Paper
- Press release
- Public Procurement
- Regulatory Efficiency
- Report
- SME
- SME Platform
- WHAT IF
- White paper
22/11/2021
08/11/2021
27/10/2021
22/10/2021
30/09/2021
What if machine learning and artificial intelligence could learn to detect one of the most common forms of blood cancer, through evaluating data based on the gene activity of blood cells?
27/08/2021
EuropaBio comments on the public consultation on blue bioeconomy.
10/08/2021
EuropaBio comments on the public consultation on blue bioeconomy.
29/06/2021
We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders to ensure that COVID vaccines and treatments get to the patients in the world who most need them.
26/05/2021
20/05/2021
The COVID-19 pandemic has been a catalyst for change which has led us to revisit the way we conduct clinical trials.
05/05/2021
EuropaBio comments on the draft delegated act on climate-related objectives under the Taxonomy Regulation.
05/05/2021
EuropaBio comments on the draft delegated act on climate-related objectives under the Taxonomy Regulation.
